Healthcare Press Releases

Three Retlif laboratories expand Scope of Accreditation for Medical Devices Testing

RONKONKOMA, NEW YORK, USA, July 26, 2021 /EINPresswire.com/ — A globally recognized, independent EMC/EMI and environmental testing organization, Retlif Testing Laboratories has achieved a significant milestone with FDA ASCA pilot program accreditation.

One of the first independent EMC (Electromagnetic Compatibility) laboratories to gain accreditation in the USA, Retlif supports conformity assessment schemes with test data from ISO/IEC 17025-accredited labs. The US Food and Drug Administration (FDA) has recently embraced accreditation through a pilot program, the Accreditation Scheme for Conformity Assessment (ASCA).

ASCA incorporates international conformity assessment standards and practices with the goal of increasing confidence in medical device testing among FDA reviewers and medical device manufacturers. Anticipation is that this will decrease requests for additional information relating to testing methodologies when pre-market submissions include a declaration of conformity to an FDA-recognized consensus standard within the FDA ASCA Pilot Program.

Scopes of Accreditation include basic EMC requirements contained within IEC 60601-1-2, Edition 4.0, 2014 including requirements for medical electrical equipment and systems used in home health care and emergency medical services environments. According to Retlif President Walter Poggi, "product testing applications are extensive. They range from electrocardiographs and endoscopic equipment to ultrasonic diagnostic and monitoring equipment, to x-ray equipment for computed tomography. Dental intra-oral x-ray equipment are also included. The Pilot program is intended to increase consistency and predictability in the FDA's approach to assessing conformance with FDA-recognized consensus standards and test methods eligible for inclusion in the ASCA Pilot in medical device premarket reviews."

Medical equipment manufacturers can readily access this alternative path for FDA acceptance of EMC test reports from Retlif. All three Retlif EMI/EMC facilities (Harleysville PA, Goffstown NH and Ronkonkoma NY) have achieved FDA ASCA Pilot Program accreditation.

For more information contact ASCA@Retlif.com.

About Retlif Testing Laboratories:

Founded in 1978 and headquartered in Ronkonkoma, New York, USA, Retlif Testing Laboratories is one of the USA’s highest profile independent testing laboratories. Retlif provides complete EMC/EMI and Environmental Simulation Testing and engineering services for medical, aerospace and aviation, avionics, rail and transit, maritime, military, defense, and homeland security products. Retlif’s test data is recognized worldwide. The organization is strategically focused on test results with a mission to provide tangible customer value through testing and engineering services.

James Stanco
Progressive Marketing Group, Inc.
email us here
Visit us on social media:
LinkedIn

Source: EIN Presswire

RACINE, WI, UNITED STATES, July 26, 2021 /EINPresswire.com/ —

When you hear from God and you are certain that it is His voice, not just a notion — you move! Well Kenya McRae listened to that still small voice, and she has become an entrepreneur extraordinaire. Her latest accomplishment includes a line of protective gear, right in time for the next wave of the highly infectious Delta variant. The idea for Kenya’s hygiene friendly protective items came to her because of her brother being hospitalized where he contracted a deadly staph infection.

It is a well-known fact that health care associated infections, (HCAIs) as they are called are a leading problem in the medical field. Many patients die each year from complications related to their exposure to these microorganisms and the resulting disease. Kenya’s revolutionary preventative layers help the patient by creating a sanitary guard over well trafficked items like urinals and wheelchair armrests where these clusters of germs are lurking.

With the explosion of lockdown weary travelers, Kenya has thought of everything to keep you safe in the air, rails and buses. A study conducted by Auburn University found that harmful and potentially deadly germs and bacteria such as MRSA and E. coli survive for up to 7-8 days on airplane seats, exposing you to great danger. Her reusable seat covers are versatile enough to fit most seats and smart sojourners use it at the doctor’s office, on trains and anywhere you want to sit safely.

Your seat is not the only place you need protection. Consider the tray you eat on during your travels. Time Magazine found that the tray tables had cold viruses, human parainfluenza viruses, norovirus (which can cause diarrhea and vomiting) and the superbug MRSA that causes skin infections. Kenya’s tray covers protect you while you munch and work in perfect peace.

And last, but not at all least, Kenya created covers for those extremely dirty shopping cart handles which has more than 270 times more bacteria than your toilet handle and 361 times more bacteria than a restroom doorknob! And did you know researchers say 75% of those bacteria are very harmful to your body? Pardon the pun but Kenya McRae’s “got you covered.”

This trailblazing serial entrepreneur, last seen on The Word Network, flourishes in every lane she touches from BBQ sauce to sold out speaking engagements, Kenya is in a class by herself. The self-made mogul with a heart after God holds a master’s degree in Business Administration.

With every new venture and measure of success Kenya would be the first to give God all the glory for all the mighty things that He has done in her life.

For more information about protective gear or to interview Kenya McRae, please go to www.coveritcovers.com or www.kenyamcrae.com.

Kenya McRae
CoverIt Covers
+1 608-571-3284
email us here

Kenya McRae on The Word Network

Source: EIN Presswire

Dr. Robert Bianchini joins Laboratory Skin Care®, Inc. Board of Directors

SAN FRANCISCO BAY AREA, CA, UNITED STATES, July 26, 2021 /EINPresswire.com/ — Laboratory Skin Care, Inc. (LSC) announced today the appointment of Dr. Robert Bianchini to its Board of Directors. The company offers a game changing dermal delivery platform that redefines the way cosmetic and pharmaceutical actives are delivered through the skin.

“We are pleased to welcome Dr. Bianchini to LSC’s Board and we look forward to his industry insight,” said LSC Founder and CEO, Zari Mansouri. “Bob brings extensive expertise that will further LSC’s effort to improve the health and well-being of consumers around the world, utilizing our next generation platform dermal delivery technology, Hydroxysomes^®.”

Dr. Bianchini is an investor and an advisor for private equity firms and leading consumer brands. He has served in operational and leadership roles across all facets of the consumer product, pharmaceutical, and chemical Industries. He served as an executive at Rodan and Fields, Johnson and Johnson, Merck and Co., among others. He carries a proven track record of rapidly growing top and bottom-line P&L’s and a highly lauded reputation for creating high performing teams, driving growth, identifying novel technology solutions and bringing innovative products to market.

“I am excited to join LSC’s impressive Board of Directors, and look forward to working with them on their expansion plans,” shared Dr. Bianchini. “The company’s proven success in developing highly effective actives and finished products for the pharmaceuticals and personal care products industries, makes them a leader in their field. Their new GMP manufacturing location in Hayward, CA has great potential to expand its product offerings to other therapeutic areas, including transfection reagents."

LSC is a life sciences biotechnology company with more than 100 issued patents and pending applications that are 100% owned, and not sub-licensed. LSC’s research, pilot lab, as well as corporate offices are headquartered in San Francisco Bay Area. The company offers a broad pipeline of technologies for pharmaceutical and cosmetic products.

“We are delighted to have Bob join LSC’s Board of Directors,” shared fellow board member Bret Field, Esq. “He brings a wealth of knowledge and industry experience to LSC which will be invaluable as the company advances its current and future objectives.”

Dr. Bianchini joins LSC’s existing board members:
● Zari Mansouri, LSC founder & CEO
● Dr. Tom Gadek, Director
● Dr. Winfried Kuhlmann, Director
● Bret Field, Esq., Director

About

Laboratory Skin Care^®, Inc. (LSC) is a privately-held biotechnology company that was established in the San Francisco Bay area in 1993 to develop, manufacture and commercialize dermal, trans-dermal and sub-dermal delivery technologies for use in cosmetic skin care products, prescription dermatologicals, and other pharmaceutical products. LSC products and technologies have enjoyed worldwide commercial success through incorporation in multiple leading-brand skin care products. LSC’s patented flagship technology, Hydroxysomes^®, is a non-liposome- and non-polymer-based micro-carrier platform dermal delivery system. For more information, visit https://lsc-inc.com/.

Contact

Laboratory Skin Care^®, Inc.
Phone: +1-650-373-0450
Email: info@lsc-inc.com

Travis Pate
Laboratory Skin Care®, Inc.
+1 650-373-0450
email us here

Source: EIN Presswire

AHMC Healthcare invests millions to support Seton Medical Center in Daly City, California.

Seton is Largest Employer in Daly City with 1,100 Jobs

DALY CITY, CALIFORNIA, UNITED STATES, July 25, 2021 /EINPresswire.com/ — AHMC Healthcare has launched a $60 million project to modernize and seismically retrofit AHMC Seton Medical Center in Northern California. The hospital and surrounding buildings will remain open for patient care during the year-long renovation that starts this week. This $60 million investment is in addition to the $100 million AHMC has devoted since it purchased the hospital in April 2020.

“AHMC is investing $60 million to retrofit and modernize Seton Medical Center’s to continue its history of providing vital community care and acute medical services to San Mateo County and San Francisco County,” said Dr. Kenneth Sim, chairman of AHMC Seton Medical Center.

AHMC bought Seton out of bankruptcy from Verity Health in August 2020 in the midst of the COVID-19 pandemic. During the pandemic the hospital served as a lifeline for COVID-19 patients when Governor Gavin Newsom announced the State would lease more than half its beds as part of the state’s emergency response to the pandemic.

“The new seismic retrofit and investments totaling $160 million to support new medical equipment and facility upgrades demonstrates AHMC is committed to keeping the failing hospital alive to service the community,” Sim said.

Seton is the largest employer in Daly City. AHMC’s purchase of Seton and its investments have preserved the 1,100 jobs at the hospital, including physicians, nurses, and union members. The hospital serves 27,000 patients annually.

This is AHMC’s first Northern California hospital. Based in southern California, AHMC operates more than 1,200 beds at seven acute care facilities and employs over 7,000 caregivers. Seton also operates Seton Coastside, a 116-bed skilled nursing facility with a 24-hour standby emergency department in Moss Beach.

“AHMC’s focus is on ensuring Seton’s longstanding operations and service to San Mateo and San Francisco counties, and the California coastline. This hospital is vital because without it is a healthcare desert, as there are few nearby alternatives for our community,” Sim added.

AHMC is committed to increasing the overall health of the community, he said. Seton plays an important role in meeting community needs including emergency care, cardiac services, critical care, women’s health services, skilled nursing, sub-acute, psychiatric services, cancer care, diagnostic and imaging services, and as a designated STEMI receiving and advanced certification as a Primary Stroke Center.

“AHMC Seton Medical Center stands as a beacon on the hill for so many of us who were born at Seton and raised in the community,” said Fred Naranjo, Vice Chairman at Seton Medical Center. “This project ensures that the hospital continues to provide patient care in the decades ahead.”

Swinerton construction in in charge of the retrofit and modernization of Seton Medical Center including its landmark tower, which was built in 1963. The hospital is a cast-in-place concrete structure consisting of a central tower (floors 3-10) built on top of a podium (floors lower level to 2). The seismic upgrade project consists of new grade beams, structural upgrades to existing beams and columns, and ADA upgrades.

“Our physicians and staff are appreciative that there is no disruption to patient care while the project is underway,’ said Dr. Brian Grady, President of the Medical Staff.

AHMC Seton Medical Center celebrated this milestone at an official groundbreaking ceremony today with Congresswoman Jackie Speier; San Mateo County Supervisors David Canepa and Don Horsley; Sen. Scott Weiner; Assemblyman Phil Ting; Daly City Mayor Juslyn Manalo; Colma Mayor Diana Colvin; San Francisco Supervisor Ahsha Safai; Beth Andersen, California Plan President, Anthem; Jennifer Lauritzen, Project Executive, Swinerton construction; and Sarkis Vartanian, Seton interim CEO, as well as Dr. Sim, Linda Marsh, Fred Naranjo of AHMC Healthcare, and a representative of California Governor Gavin Newsom, and union leaders. More than 250 attendees were in attendence.

About AHMC Seton Medical Center

AHMC Seton Medical Center has been serving the health care needs of San Francisco and northern San Mateo County since its founding 127 years ago as Mary’s Help Hospital in 1893.

About AHMC Healthcare

AHMC is a privately held hospital corporation based in the Greater San Gabriel Valley of California. Jonathan Wu is the founder and Chairman of AHMC. AHMC operates more 1,200 beds at its seven acute care facilities and employs over 7,000 caregivers.

Sam Singer
Singer Associates Public Relations San Francisco
+1 415-227-9700
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Source: EIN Presswire

LAGUNA HILLS, CALIFORNIA, USA, July 24, 2021 /EINPresswire.com/ — In this video, Louix gives two powerful techniques to help identify, and break down, patterns of control.

To learn more about Louix Dor Dempriey and his non-profit educational foundation, as well as his teachings and events, please visit: www.Louix.org.

About the Louix Dor Dempriey Foundation

The Louix Dor Dempriey Foundation is a 501(c)(3) non-profit educational organization dedicated to sharing the teachings and humanitarian works of Louix Dor Dempriey. Its mission is to help people remember and restore their inherent divinity, and to walk in this world as unconditional love.

Louix Dor Dempriey is a spiritual Master who has dedicated his life to helping other people attain self-mastery in all areas of their lives, so that they, too, can experience true joy and inner peace, regardless of worldly circumstances. Louix's darshan, as well as his illuminating discourses, meditations, and ceremonies, have invoked profound transformation in thousands of people worldwide. With grace and humor, Louix imparts timeless wisdom in contemporary, practical teachings—that transcend all faiths, paths, religions, and cultures. He resides at Prema Drala Ashram in Laguna Hills, California.

For more information, please visit: http://www.Louix.org.

Samantha Farber
Louix Dor Dempriey Foundation
+1 888-288-3735
email us here
Visit us on social media:
Facebook
Twitter

Source: EIN Presswire

A World Renowned Urologist to lead and scale Veyond Metaverse's medical organization to drive the company through the next phase of innovation

SAN FRANCISCO, CALIFORNIA, USA, July 24, 2021 /EINPresswire.com/ — Veyond Metaverse, Inc., a leader in the field of extended reality (XR) and metaverse technology for the healthcare segment, today announced the appointment of Thierry Alain Flam, M.D., to the newly created position of chief medical officer, where he will oversee global clinical development and surgical initiatives for Veyond Metaverse. Dr. Flam, a world-renowned urologist, brings more than 30 years of experience in surgical, clinical, and basic research in the field of urologic oncology, mainly in the treatment of prostatic cancer. In 1998, Dr. Flam was the first to introduce permanent seed prostatic brachytherapy at the Curie Institute in France. He collaborated with the Pasteur Institute on the research on bladder cancer and has published extensively.

"We are thrilled that Thierry is bringing to Veyond Metaverse his strong medical, clinical, and industry leadership at a time when our surgical platform is advancing in product development," said Adam Choe, chief executive officer of Veyond Metaverse. "Thierry has deep experience in clinical and basic research and surgical development, including the surgical simulators, which will prove valuable for our product development strategies. His career-long focus on patient quality of healthcare delivery solutions is an excellent fit with our vision and culture, which is dedicated to making a fundamental difference in patients' lives."

"I'm excited to join Veyond Metaverse at this time of important growth and evolution for the company," said Dr. Flam. "Veyond Metaverse is leading the XR solutions in the field of surgery, mental (brain) health, and mobile delivery system."

About Veyond Metaverse
Veyond Metaverse offers a new and disruptive XR technology to medical education, surgical planning, and training, augmented assisted surgical operations, pharmaceutical, oncology treatment, and diagnosis. Our proprietary communication platform enables global engagement and collaboration seamlessly, creating a more accessible, user-friendly ecosystem by leveraging the most advanced communication capabilities. We seek to improve medical education, surgical training, save patients' lives by enhancing surgery, diagnosis, and expand worldwide access through the proprietary cloud platform. Veyond Metaverse is based in Silicon Valley, CA. Visit www.veyondmetaverse.com

Media Contact
Adam Choe
adam@veyondmetaverse.com

Adam Choe
Veyond Metaverse
adam@veyondmetaverse.com

Source: EIN Presswire

Collagen market globally is anticipated to reach USD 7.73 billion by 2027; growing at a CAGR of 7.2% by Revenue and 5.3% by Volume from 2020 to 2027.

PATNA, BIHAR, INDIA, BIHAR, INDIA, July 24, 2021 /EINPresswire.com/ — Collagen market globally is anticipated to reach USD 7.73 billion by 2027; growing at a CAGR of 7.2% from 2020 to 2027. In terms of volume, the global collagen market would foresee a CAGR of 5.3% from 2020 to 2027. Collagen is a protein found inside various connective tissues of a mammal’s body in abundance. It is an essential component in food products and the healthcare industry. It has high nutritional qualities which lead to skin and health benefits in a body. Further, an outbreak of COVID-19 has led to increased health awareness among people on a larger scale. As a result, people are now keen towards buying tropical fruits, bone broth, and citrus fruits among others. Consumption of such products helps the body to produce collagen reducing skin and hair problems again leading to the growth of the market.

Request a Sample at
https://www.accurizemarketresearch.com/report/collagen-market/sample-request

The report has been compiled through extensive research and analysis. The scope of the global collagen market is widely expanded to the industry namely food and beverages, pharmaceuticals, cosmetics, and other supplements. This report explains the key players who are dominant in the market and also about the market dynamics impacting the market. The segmentation covered under the scope of global collagen market is by product which is further segmented into Gelatin, Hydrolyzed Collagen, Synthetic Collagen, Native Collagen, and Others, by source market which is bifurcated into Bovine, Porcine, Marine, Poultry, and others. Further, by dosage, by the dosage form, the market is segmented into Liquid, Powder, Capsule/Tablets, and others and by application, the market is categorized into food and beverages, skincare, and cosmetics, nutraceuticals, healthcare, and pharmaceuticals. By geography, the major geographies cover under the scope of the study is North America, Europe, Asia Pacific, and the Rest of the world (RoW). The key countries across these major geographies are also covered under the scope of the study.

One of the major drivers in the global collagen market is the health awareness among people and as a result, it has promoted more number of industries and has applications across industries such as healthcare, skincare supplements, healthy food and beverages like meat, desserts, and other products which help a human body in the creation of collagen, thus resulting in the growth of overall collagen market. Also, rising personal grooming trends have enhanced the statistics of the collagen industry. One of the major restraints in this market is that the industry is regulated by rules and laws which govern animal-based raw materials used in collagen production. Hence, animal killing for obtaining collagen is also a major issue. Also, lockdowns have impacted manufacturing as a result which has also affected supply chains Opportunities are coming up for the pharmaceuticals and nutraceuticals because of the increase in coronavirus cases which is creating a need to boost the immunity of a person.

The key players in the global collagen market are Gelita AG (Germany), Nitta Gelatine, Inc. (US), Weishardt Group (France), Darling Ingredients (US), and Nippi Inc. (Japan), Weishardt International, Rousselot B.V, Collagen Matrix Inc., Koninklijke DSM N.V., CONNOILS LL, and Advanced BioMatrix, Inc., ChinaTech Peptide Co. Ltd, Amicogen Inc., and Norland Products Inc. among others.

Looking for a Customized Report or Discount? Enquire at
https://www.accurizemarketresearch.com/report/collagen-market/ask-for-customization

Market Scope and Segmentation of Global Collagen Market:

By product
• Gelatin
• Hydrolyzed Collagen
• Synthetic Collagen
• Native Collagen
• Others

By Source
• Bovine
• Porcine
• Marine
• Poultry
• Others

By Dosage Form
• Liquid
• Powder
• Capsule/Tablets
• Others

By Application
• Food and Beverages
o Desserts
o Meat and chicken
o Fruits and nutritional products
o Snacks and Cereals
o Bakery & confectionery products
o Dairy products
• Skin Care and Cosmetics
o Beauty Cosmetics
o Skin & Haircare products
o Beauty supplements/ Nuticosmetics
• Nutraceuticals
o Dietary supplements
o Functional food
• Healthcare and pharmaceuticals
o Orthopedic
o Wound care
o Dental
• Others

By Region
• North America
o The U.S.
o Mexico
o Canada
• Europe
o The U.K.
o Germany
o France
o Italy
o Spain
o Belgium
o Switzerland
o Netherlands
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Taiwan
o Singapore
o Australia
o Rest of Asia Pacific
• Rest of the World (RoW)
o Central & South America
o Middle East
o Africa

About Us
Accurize Market Research (AMR) is a full-service market research and business-consulting company that provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. We at Accurize Market Research provide syndicated as well as customized reports across domains namely Consumer Goods, Food & Beverages, Medical Devices, Mining Equipment, Automation, Manufacturing, Healthcare & Medical, and Defense & Aerospace, Semiconductor & Electronics, Construction, Information and Communication, Banking, Financial Services and Insurance (BFSI), and Energy among others. These industry vertical areas are further studied and analyzed across different geographies namely North America, Europe, Asia Pacific, and the Rest of the World (RoW). The countries across these major geographies are also covered under the scope of our study; such as the U.S., Mexico, and Canada under North America; UK, Germany, Russia, Germany, and France among others under Europe. Similarly, China, India, Taiwan, South Korea, Australia, Singapore, and Japan among others are covered under the Asia Pacific. The rest of the World (RoW) includes South & Central America, Middle East, and Africa. Further, as per the scope countries across South & Central America, Middle East, and Africa would also be studied separately under the scope of the report.

Available Report Format: Excel/PDF/PPT/Word

Contact:

Rakesh K Singh
Head – Business Development
Patna Office (Asia):
K-129, PC Colony, Hanuman Nagar, Kankarbagh, Patna,
PIN – 800020
Tel: +1-339-368-6383/ +91-9665120699
Email: help@accurizemarketresearch.com

Web: https://www.accurizemarketresearch.com/

Accurize Market Research Blog:
https://www.accurizemarketresearch.com/blog-list

Rakesh Kumar Singh
ACCURIZE MARKET RESEARCH PVT LTD
+91 9665120699
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Source: EIN Presswire

VAN NUYS, CALIFORNIA, UNITED STATES, July 23, 2021 /EINPresswire.com/ — The San Fernando Valley has the honor of being home to immigrants from all over the world who have created families, pursued careers, and created to our society in immeasurable ways. The COVID-19 Pandemic has made life immeasurably harder for vulnerable immigrants. Some immigrants fear that information taken during vaccinations could be turned over to authorities, and they have been hesitant to seek out vaccines, while those language barriers or English as their second language may find it difficult to access them.

To overcome these barriers on Saturday, July 24, 2021, Valley Care Community Consortium (VCCC) is partnering with Hermandad Mexicana Nacional in coordinating a Pop-Up Vaccine Clinic from its Panorama City location at 7915 Van Nuys Boulevard, Panorama City, CA 91402. Hosting the Vaccine Clinic from Hermandad Mexicana Nacional should alleviate some of the warranted anxiety community residents have while seeking COVID-19 Vaccination.

For more than 40 years, Hermandad Mexicana Nacional has strengthened and provided support to the immigrant community. The organization is dedicated to providing services and protecting the needs and rights of Spanish-speaking immigrants. With more than offices in Los Angeles County, Orange, Ventura, San Bernardino, and San Diego, Hermandad Mexicana Nacional has become a prestigious organization in citizenship and immigration services. It will be promoting the Pop-Up Vaccine Clinic throughout all of its locations.

Valley Care Community Consortium (VCCC) is supporting this significant community-based event. Founded in 1994, VCCC serves the San Fernando and Santa Clarita Valley’s as the health and mental health planning collaborative. Equity drives our mission, and we were founded to further health care access for the uninsured and underinsured.

As part of this work, we are supporting Los Angeles County COVID-19 Equity program as Community Outreach & Education Grantees. Effective community outreach utilizes grassroots models of engagement to ensure accurate and up-to-date information regarding COVID-19, especially those who are most impacted. The Northeast San Fernando Valley is chronically underserved, and just 38 percent of community residents within North Hills, Pacoima, Panorama City, and Van Nuys are fully vaccinated . This is a stark comparison to affluent San Fernando Valley cities of Encino, Porter Ranch, and Sherman Oaks where 52 percent of community residents are fully vaccinated. The unequitable rate of fully vaccinated community residents results in greater rates of adverse outcomes, hospitalizations, and deaths1.

In an effort to meet community residents in non-traditional settings, VCCC has secured participation of a Los Angeles County Department of Public Health COVID-19 Mobile Clinic to provide vaccine at the Pop-Up Vaccine Clinic. The two vaccines that will be administered are Johnson & Johnson and Pfizer.

VCCC’s Community Advocate Team will be on-hand to support registration, provide important after-care instructions, and describe activities that are safer for fully vaccinated community residents to participate in. VCCC will be distributing hygiene kits and health education incentives to the first 100 community residents vaccinated at the Pop-Up Vaccine Clinic.

VCCC is requesting in-kind support from for-profit partners that will be distributed directly to community residents on the day of the Pop-Up Vaccine Clinic. To learn how your organization can contribute, please contact Scott Brumer, Director, VCCC, by email at scott.brumer@valleyccc.org or phone at (818) 800-6167.

Scott Brumer
Valley Care Community Consortium
+1 (818) 800-6167
email us here

Source: EIN Presswire

Online Coaches, Therapists, and Counselors can now tap into a rapidly growing network of Journalers seeking 1:1 and Group counseling.

FORT MYERS, FL, USA, July 23, 2021 /EINPresswire.com/ — Fort Myers, FL, USA, July 23, 2021

JournalOwl^® announces a fully integrated practice management solution for online coaches, psychotherapists, and counselors. Along with the new functionality, therapists are provided with a free directory listing to promote their practice and specialty. The new practice management feature for psychotherapists provides a multi-modal approach for live video therapy and SMS text therapy.

“Journalers asked for a schedule free way of receiving focused counseling from trained therapists. TouchPoint is the answer to our community’s demand. Online therapists can now use TouchPoint to accept and manage a much larger caseload,” explains Christina Angerer, Co-Founder. “Clients and Psychotherapists interact through an unscheduled timeline of secure videos, text messages, and secure audio. A therapist can assign journaling tasks and provides recommendations to help clients overcome a wide array of mental health challenges,” adds Angerer.

For a low yearly fee, therapists and counselors can collect payments from private clients to participate in TouchPoint. Therapists also have the option of setting a ‘per session’ rate and scheduling synchronous sessions with clientele via LivePoint. This secure HIPAA-compliant video communication option is for online therapists who prefer ‘live’ counseling sessions. The platform provides a one-stop shop for online coaches to collect client payments, manage client relationships, and grow their coaching business – all while receiving new leads from JournalOwl’s global community.

About JournalOwl

JournalOwl^® is a refreshingly simple behavior change platform that incorporates a holistic approach of journaling tasks, daily rituals, and focused coaching to build well-being and resilience. Our proprietary Cognitive Behavior Therapy (CBT) Machine Learning technology helps everyday people quickly identify thought distortions in their daily writings. JournalOwl is helping people live more productively, with less stress, and improved overall well-being.

Christina Angerer
JournalOwl LLC
+1 619-329-7958
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Source: EIN Presswire

WESTLAKE, TEXAS, USA, July 23, 2021 /EINPresswire.com/ — Virbac Corporation has announced the availability of CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED, an oral solution for the control of atopic dermatitis in dogs. While veterinarians in the United States are familiar with cyclosporine in capsule form, CYCLAVANCE™ oral solution represents the first FDA-approved liquid cyclosporine for dogs in the US.

Dr. Cristiano von Simson, Marketing and Veterinary Services Director at Virbac explained that "Atopic dermatitis in dogs is a common chronic relapsing skin disease characterized by itchy and inflamed skin. The condition can cause discomfort and pain in dogs and often requires lifelong management. Recommending a product that is easy for the client to administer correctly can significantly improve the long-term satisfaction with the treatment."

Treatment guidelines from the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) underscore the need for a multimodal approach to treating atopic dermatitis that also includes a plan for broad inflammation management.(1,2) In addition to removing or avoiding known flare factors, the ICADA Guidelines recommend cyclosporine as part of a multi-faceted approach to controlling acute flare-ups.(1,2)

CYCLAVANCE™ oral solution is also cited for having a higher acceptance rate by dogs when compared to cyclosporine capsules.(2,3) As a liquid formulation, CYCLAVANCE™ oral solution has been shown in studies to have a greater than 98% acceptance rate by dogs when administered either directly in the mouth or mixed with a small amount of food.(3) The delivery system also allows for precise dosing at 5 mg/kg for all dogs, with greater accuracy than when dosing with capsules.

“The management of atopic dermatitis is complex and our thinking about it has evolved in recent years,” notes Dr. von Simson. “The ICADA Guidelines acknowledge the importance of cyclosporine as part of a multimodal treatment approach—an approach that includes a plan for managing both inflammation and pruritus.”
Important Safety Information:

CYCLAVANCE™ (cyclosporine oral solution)(USP Modified): For use in dogs only. Wear gloves during and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose of CYCLAVANCE Oral Solution for Dogs. CYCLAVANCE Oral Solution for Dogs should be used with caution: 1) in cases with diabetes mellitus as it may cause elevated levels of serum glucose; 2) in dogs with renal insufficiency since the effect of cyclosporine use on dogs with compromised renal function has not been studied; 3) in simultaneous administration with drugs that suppress the P-450 enzyme system, such as azoles (e.g. ketoconazole), that may lead to increased plasma levels of cyclosporine. Killed vaccines are recommended for dogs receiving CYCLAVANCE Oral Solution for Dogs because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

(references)

References: 1. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21:233-248. 2. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210:1–15. 3. Navarro C, Crastes N, Benizeau E, McGahie D. Voluntary acceptance and consumption of two oral ciclosporin formulations in dogs: two randomised, controlled studies. Ir Vet J. 2015;68:3.

Focusing on animal health, from the beginning

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Michael Albo
Virbac
+1 682-647-3597
email us here

Source: EIN Presswire